Mecox Pharma-B Starts Patient Enrollment in Phase Ib/II Trial of MT1002 for Acute Ischemic Stroke

Mecox Pharma-B (02335.HK) said its Phase Ib/II clinical trial of MT1002, an in-house acute ischemic stroke candidate, has enrolled its first patient, according to 36Kr. The company described MT1002 as a dual-target antagonist of coagulation factor II and GPIIb/IIIa, with both anticoagulant and antiplatelet effects. The multicenter Phase Ib/II study is designed in two parts: the first evaluates safety and pharmacokinetics, while the second will further assess the therapy in a larger patient population through randomization and comparison against standard treatment. Mecox Pharma-B listed on the Hong Kong Stock Exchange on June 24, 2026.